Compare Stocks

Date Range: 

 resTORbioForte BiosciencesViking TherapeuticsKala PharmaceuticalsSpectrum Pharmaceuticals
SymbolNASDAQ:TORCNASDAQ:FBRXNASDAQ:VKTXNASDAQ:KALANASDAQ:SPPI
Price Information
Current Price$14.24$32.64$5.90$5.43$3.08
52 Week RangeSellBuyBuyBuyBuy
MarketRank™
Overall Score0.81.71.61.71.5
Analysis Score0.03.53.63.43.4
Community Score2.53.53.52.62.8
Dividend Score0.00.00.00.00.0
Ownership Score0.80.80.81.70.8
Earnings & Valuation Score0.60.60.00.60.6
Analyst Ratings
Consensus RecommendationSellBuyBuyBuyBuy
Consensus Price TargetN/A$82.00$16.89$21.33$9.75
% Upside from Price TargetN/A151.23% upside186.25% upside292.88% upside216.56% upside
Trade Information
Market Cap$519.11 million$441.03 million$460.79 million$350.68 million$479.60 million
Beta2.430.232.020.432.51
Average Volume1,153,737176,4441,280,2752,336,0482,600,078
Sales & Book Value
Annual RevenueN/A$40,000.00N/A$6.07 million$109.33 million
Price / SalesN/A11,025.79N/A57.774.39
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.24 per share$6.81 per share$3.83 per share$0.86 per share$1.69 per share
Price / BookN/A4.79N/A6.311.82
Profitability
Net Income$-82,740,000.00$-63,520,000.00$-25,780,000.00$-94,350,000.00$-112,690,000.00
EPS($2.41)($40.33)($0.36)($2.76)($1.14)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-1,794.36%N/A
Return on Equity (ROE)-78.12%-417.87%-13.57%-93.73%-98.90%
Return on Assets (ROA)-71.63%-248.28%-13.14%-43.09%-69.77%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.68%0.05%
Current Ratio20.69%8.97%27.08%9.11%3.48%
Quick Ratio20.69%8.97%27.09%8.73%3.48%
Ownership Information
Institutional Ownership Percentage46.19%53.03%54.13%67.63%63.56%
Insider Ownership Percentage11.80%10.90%3.70%34.15%5.04%
Miscellaneous
EmployeesN/A918188175
Shares Outstanding36.45 million13.51 million78.10 million64.58 million155.71 million
Next Earnings DateN/A5/10/2021 (Confirmed)8/4/2021 (Estimated)8/5/2021 (Estimated)5/13/2021 (Confirmed)
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Were Keeping An Eye On Spectrum Pharmaceuticals (NASDAQ:SPPI) Cash Burn RateWe're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate
nasdaq.com - May 7 at 5:18 PM
Spectrum Pharmaceuticals (SPPI) Scheduled to Post Quarterly Earnings on ThursdaySpectrum Pharmaceuticals (SPPI) Scheduled to Post Quarterly Earnings on Thursday
americanbankingnews.com - May 7 at 9:33 AM
Spectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate UpdateSpectrum Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Corporate Update
businesswire.com - May 6 at 11:15 AM
Spectrum Pharmaceuticals, Inc. Expected to Post FY2022 Earnings of ($0.42) Per Share (NASDAQ:SPPI)Spectrum Pharmaceuticals, Inc. Expected to Post FY2022 Earnings of ($0.42) Per Share (NASDAQ:SPPI)
americanbankingnews.com - May 6 at 11:12 AM
-$0.33 Earnings Per Share Expected for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) This Quarter-$0.33 Earnings Per Share Expected for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) This Quarter
americanbankingnews.com - May 3 at 4:40 AM
Now Is A Good Time To Buy Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)Now Is A Good Time To Buy Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
marketingsentinel.com - April 30 at 2:19 PM
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Stock Could Reward Investors With a 381.1% GainSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Stock Could Reward Investors With a 381.1% Gain
marketingsentinel.com - April 21 at 1:00 PM
Attention Investors: What’s Really Happening to Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)Attention Investors: What’s Really Happening to Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
stocksregister.com - April 20 at 3:03 PM
 Brokerages Expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Will Announce Earnings of -$0.33 Per Share Brokerages Expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Will Announce Earnings of -$0.33 Per Share
americanbankingnews.com - April 17 at 3:12 AM
Double dose of Spectrum Pharmas poziotinib improves tolerability in NSCLC patientsDouble dose of Spectrum Pharma's poziotinib improves tolerability in NSCLC patients
seekingalpha.com - April 14 at 12:34 AM
Check This Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Analysis Before You InvestCheck This Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Analysis Before You Invest
stocksregister.com - April 12 at 8:35 AM
Spectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing DataSpectrum Pharmaceuticals Presentations at the Upcoming AACR Virtual Meeting 2021 to Include Updated Poziotinib Twice Daily Dosing Data
finance.yahoo.com - April 5 at 9:38 AM
BRIEF-Spectrum Pharmaceuticals Reports Fourth Quarter 2020 And Full Year 2020 Financial ResultsBRIEF-Spectrum Pharmaceuticals Reports Fourth Quarter 2020 And Full Year 2020 Financial Results
msn.com - March 30 at 8:05 PM
Spectrum Pharma: Q4 Earnings SnapshotSpectrum Pharma: Q4 Earnings Snapshot
ourmidland.com - March 30 at 8:05 PM
Spectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline UpdateSpectrum Pharmaceuticals Reports Fourth Quarter 2020 and Full Year 2020 Financial Results and Pipeline Update
finance.yahoo.com - March 30 at 8:04 PM
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate UpdateSpectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
finance.yahoo.com - March 26 at 8:16 PM
Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval InspectionSpectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection
finance.yahoo.com - March 16 at 10:27 AM
Spectrums (SPPI) NSCLC Drug Gets FDAs Fast Track DesignationSpectrum's (SPPI) NSCLC Drug Gets FDA's Fast Track Designation
finance.yahoo.com - March 12 at 5:31 PM
SPPI Stock Price Increases Over 20% Pre-Market: Why It HappenedSPPI Stock Price Increases Over 20% Pre-Market: Why It Happened
pulse2.com - March 11 at 12:49 PM
FDA Grants Fast Track Designation to Spectrum Pharmaceuticals’ PoziotinibFDA Grants Fast Track Designation to Spectrum Pharmaceuticals’ Poziotinib
finance.yahoo.com - March 11 at 7:49 AM
How Much Of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Do Institutions Own?How Much Of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Do Institutions Own?
finance.yahoo.com - March 3 at 1:16 PM
Spectrum Pharmaceuticals Presents Twice Daily Dosing Data for Poziotinib at the ESMO TAT Virtual Congress 2021Spectrum Pharmaceuticals Presents Twice Daily Dosing Data for Poziotinib at the ESMO TAT Virtual Congress 2021
finance.yahoo.com - March 2 at 2:42 PM
Spectrum Pharmaceuticals Announces Poster Presentation at Upcoming Miami Breast Cancer ConferenceSpectrum Pharmaceuticals Announces Poster Presentation at Upcoming Miami Breast Cancer Conference
finance.yahoo.com - February 26 at 7:41 AM
Spectrum Pharmaceuticals Announces Two Presentations at Upcoming ESMO TAT Virtual Congress 2021Spectrum Pharmaceuticals Announces Two Presentations at Upcoming ESMO TAT Virtual Congress 2021
finance.yahoo.com - February 23 at 9:57 AM
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): It Is A Stock Worth Considering TodaySpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI): It Is A Stock Worth Considering Today
marketingsentinel.com - February 5 at 7:38 PM
DateCompanyBrokerageAction
5/28/2020resTORbioFIG PartnersReiterated Rating
4/29/2020resTORbioEvercore ISIUpgrade
11/15/2019resTORbioSVB LeerinkDowngrade
11/15/2019resTORbioWedbushDowngrade
11/15/2019resTORbioGuggenheimDowngrade
11/15/2019resTORbioCantor FitzgeraldDowngrade
4/1/2021Forte BiosciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
3/26/2021Forte Biosciences(FBRC)Initiated Coverage
3/23/2021Forte BiosciencesChardan CapitalLower Price Target
8/28/2020Forte BiosciencesBrookline Capital ManagementInitiated Coverage
8/25/2020Forte BiosciencesTruist SecuritiInitiated Coverage
6/22/2020Forte BiosciencesLADENBURG THALM/SH SHInitiated Coverage
1/22/2021Viking TherapeuticsStifel NicolausReiterated Rating
10/29/2020Viking TherapeuticsRaymond JamesBoost Price Target
9/11/2020Viking TherapeuticsWilliam BlairReiterated Rating
9/10/2020Viking TherapeuticsB. RileyReiterated Rating
9/1/2020Viking TherapeuticsBTIG ResearchBoost Price Target
8/28/2020Viking TherapeuticsHC WainwrightBoost Price Target
7/29/2020Viking TherapeuticsOppenheimerReiterated Rating
6/4/2020Viking TherapeuticsBMO Capital MarketsInitiated Coverage
5/2/2020Viking TherapeuticsMaxim GroupInitiated Coverage
11/30/2020Kala PharmaceuticalsNorthland SecuritiesReiterated Rating
9/14/2020Kala PharmaceuticalsJefferies Financial GroupDowngrade
5/27/2020Kala PharmaceuticalsJPMorgan Chase & Co.Boost Price Target
9/17/2020Spectrum PharmaceuticalsJMP SecuritiesInitiated Coverage
(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.